Elevance Health Inc.

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +45

Elevance Health, Inc. $ELV Shares Sold by AIA Group Ltd

AI-generated analysis

πŸ“‰ AIA Group Ltd lowered its Elevance Health position by 30.3% in Q1, selling 21,370 shares while retaining a $14.4 million stake.

πŸ“ˆ ORG Partners LLC increased its holding by 120.4% in Q4, acquiring an additional 59 shares to own 108 total shares.

πŸ’° Elevance Health maintains a market cap of $80.82 billion with a P/E ratio of 16.56 and a debt-to-equity ratio of 0.68.

πŸ“… The company announced a quarterly dividend of $1.72 per share, payable on September 25th to shareholders of record on September 10th.

🎯 Bank of America raised its price target from $435 to $460 and reaffirmed a 'buy' rating in a recent report.

πŸ“Š Morgan Stanley increased its target price from $352 to $404, assigning an 'equal weight' rating to the stock.

πŸ‘” Director Robert L. Dixon, Jr. sold 151 shares for approximately $60,667 in a transaction on June 11th.

πŸ₯ Elevance Health operates as a major U.S. health benefits provider offering medical plans for individuals, employers, and government programs.

πŸ“‰ The stock currently trades at $372.68, sitting below its 50-day moving average of $399.55 but above its 200-day average of $355.35.

πŸ” Institutional ownership stands at 89.24%, indicating strong interest from hedge funds and asset managers.

Bullish Signals
  • Analyst consensus is 'Moderate Buy' with an average price target of $440.90, suggesting upside potential from current levels.
  • Bank of America boosted its price target to $460 and Morgan Stanley raised theirs to $404, reflecting confidence in the company's outlook.
  • The company maintains a healthy balance sheet with a debt-to-equity ratio of 0.68 and a current ratio of 1.52.
  • Institutional investors like ORG Partners LLC significantly increased their stakes, signaling continued institutional interest.
Risk Factors
  • AIA Group Ltd reduced its position by 30.3% in the first quarter, indicating some large-scale profit-taking or de-risking.
  • Goldman Sachs restated a 'neutral' rating with a price objective of $395, which is below the current trading price of $372.68 but implies limited upside.
Full Analysis
AIA Group Ltd reduced its stake in Elevance Health, Inc. (NYSE:ELV) by 30.3% in the first quarter, selling 21,370 shares and retaining a position worth approximately $14.4 million. While AIA exited significantly, other institutional investors like Kemnay Advisory Services, J.Safra Asset Management, ORG Partners LLC, Dorato Capital Management, and Loring Wolcott & Coolidge increased their holdings during the fourth quarter, with ORG Partners notably lifting its position by over 120%. Elevance Health reported a market capitalization of $80.82 billion with key financial metrics including a price-to-earnings ratio of 16.56 and a debt-to-equity ratio of 0.68. The stock trades at $372.68, positioned between its 50-day moving average of $399.55 and 200-day average of $355.35, with an annualized dividend yield of 1.8% set to be paid on September 25th. Analyst sentiment remains cautiously positive with a consensus rating of 'Moderate Buy' and an average price target of $440.90. Major institutions like Bank of America and Morgan Stanley raised their price targets recently, while Goldman Sachs maintained a neutral stance at $395. The company continues to focus on integrated health care delivery under CEO Gail Boudreaux.